Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Iowa Healthcare Reporter.
Press releases published on August 18, 2025
Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
GlobeNewswire
·
August 18, 2025
-- Achieved Primary Endpoint with 30mg Dose of RE104 Demonstrating 23.0-Point Reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Score on Day 7, a 5.8-Point Greater Reduction Than Patients Treated with 1.5mg Dose (p=0.0094) -- -- …
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases
GlobeNewswire
·
August 18, 2025
REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting toxicities were observed with an overall favorable safety …
OneMedNet initiates new Subscription Revenue model in partnership with Circle CVI
GlobeNewswire
·
August 18, 2025
MINNEAPOLIS, Aug. 18, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD) announced a long-term strategic partnership with Circle Cardiovascular Imaging Inc. (Circle CVI …
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
GlobeNewswire
·
August 18, 2025
Shareholders stand to receive a significant and attractive cash premium, as the purchase price of US$3.01, with a contingent value right for potential additional aggregate payments of up to US$1.19 per share, represents a compelling premium of 216% to the …
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
GlobeNewswire
·
August 18, 2025
Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates; 100% CR/CRh at 80 mg and 120 mg Addition of TUS to VEN+AZA …
Theratechnologies annonce le dépôt des documents relatifs à l’assemblée extraordinaire et l’obtention d’une ordonnance provisoire concernant son acquisition par CB Biotechnology, un membre du même groupe que Future Pak
GlobeNewswire
·
August 18, 2025
Les actionnaires pourraient recevoir une prime en espèces considérable et attrayante puisque le prix d’achat de 3,01 $ US, assorti d’un droit conditionnel à la valeur représentant des paiements supplémentaires totaux pouvant atteindre 1,19 $ US par action, …
Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease
GlobeNewswire
·
August 18, 2025
LOS ALTOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the issuance of U …
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
GlobeNewswire
·
August 18, 2025
Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International …
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
GlobeNewswire
·
August 18, 2025
Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID® Separate single-arm trial will assess safety and efficacy in …
SRx Health Solutions Signed a Letter of Intent to Acquire the Assets of Royal Uranium
GlobeNewswire
·
August 18, 2025
TAMPA, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (“SRx Health” or the “Company”), a leading global health and wellness company, today announced that is has signed a non-binding Letter of Intent to purchase …
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire
·
August 18, 2025
Achieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home (Outpatient) setting sNDA submission on track for Q1 2026 NEW HAVEN, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a …
BellaSeno Establishes High-Profile Clinical Advisory Board
GlobeNewswire
·
August 18, 2025
Leading international experts to support clinical development of BellaSeno´s pioneering resorbable breast implants Pivotal clinical trial to be initiated shortly Leipzig, Germany / Brisbane, Australia, August 18, 2025 – BellaSeno GmbH, an ISO 13485- …
Clarity Health Care is Coming to Malvern
GlobeNewswire
·
August 18, 2025
MELBOURNE, Australia, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Clarity Health Care, a leading provider of multidisciplinary mental health services, is expanding its reach with the opening of a new clinic in Malvern, Victoria. Renowned for its integrated care …
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
GlobeNewswire
·
August 18, 2025
Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of …
Le vaccin IXCHIQ® de Valneva contre le chikungunya désormais autorisé au Canada pour les personnes âgées de 12 ans et plus
GlobeNewswire
·
August 18, 2025
Saint-Herblain (France), le 18 août 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que Santé Canada a accordé une autorisation de mise sur le marché pour son vaccin à dose unique, …